The Columbia University Diabetes Research Center was established in May 2003. As the focus of diabetes research at the largest academic medical center in the largest U.S. metropolitan area, the Columbia DRC promotes interactions among an outstanding research base, integrating basic and translational diabetes research with existing institutional centers of excellence in obesity, atherosclerosis, neurobiology, and cardiovascular biology. The DRC fosters translation of basic research advances, clinical training, epidemiology, and-through its partnership with the Berrie Diabetes Center-encourages diabetes related philanthropy. The Biomedical Research Base is comprised of 84 NIH-, ADA- or JDRF-funded investigators at Columbia, and 7 at sister institutions in New York City. The DRC supports core facilities in (A) Genomics;(B) Hormone &Metabolite;(E) Histopathology;(F) Mouse Phenotyping;and (G) Flow Cytometry. Additionally, the DRC makes available funding for young investigators through a pilot/feasibility grant program (P&F), and provides established scientists in other research areas at Columbia University and in neighboring institutions with the opportunity and support to enter the diabetes field through this program. The DRC supports program enrichment activities, designed to increase the awareness of diabetes research in the scientific/academic community at Columbia University;it also promotes interactions with academic institutions in the greater New York area. An administrative Core provides overall logistical support, financial oversight and integration of research efforts, shared core facilities and P&F program administration. During the past funding cycle, the DRC has endeavored to advance NIDDK's mission in diabetes by: (I) raising awareness of and interest in advanced clinical and basic diabetes research at Columbia University and in New York City;(ii) enhancing training and other diabetes-related educational opportunities for students, fellows, academic and community-based physicians;(///) attracting new investigators to diabetes research;{iv) providing state-of-the-art core facilities to enhance research of DRC members and contribute to the development of innovative methods for diabetes research and care;(v) fostering a collegial academic environment to facilitate information exchange within the institution and with other DRCs;(w) providing impetus to translate basic science discoveries into clinical care and community initiatives to improve the health of people with diabetes;and (wV) leveraging NIDDK resources with local and national philanthropic and diabetes advocacy organizations to integrate and expand P&F grants, as well as training and educational programs.

Public Health Relevance

; The Columbia University Diabetes Research Center continues to facilitate interactions among investigators from different academic backgrounds, providing material and intellectual support for initiatives that broaden our understanding of the causes of diabetes, and improve treatment outcomes;and to underwrite the operation of technical facilities for data acquisition and analysis, training opportunities for young investigators and students, and seeding funds for highly potentially transformative research projects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK063608-11
Application #
8435053
Study Section
Special Emphasis Panel (ZDK1-GRB-S (O2))
Program Officer
Hyde, James F
Project Start
2003-05-01
Project End
2018-01-31
Budget Start
2013-03-15
Budget End
2014-01-31
Support Year
11
Fiscal Year
2013
Total Cost
$1,357,235
Indirect Cost
$457,587
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Langlet, Fanny; Tarbier, Marcel; Haeusler, Rebecca A et al. (2018) microRNA-205-5p is a modulator of insulin sensitivity that inhibits FOXO function. Mol Metab 17:49-60
Proto, Jonathan D; Doran, Amanda C; Gusarova, Galina et al. (2018) Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution. Immunity 49:666-677.e6
Carli, Jayne F Martin; LeDuc, Charles A; Zhang, Yiying et al. (2018) The role of Rpgrip1l, a component of the primary cilium, in adipocyte development and function. FASEB J 32:3946-3956
Postigo-Fernandez, Jorge; Creusot, RĂ©mi J (2018) A multi-epitope DNA vaccine enables a broad engagement of diabetogenic T cells for tolerance in Type 1 diabetes. J Autoimmun :
Proto, Jonathan D; Doran, Amanda C; Subramanian, Manikandan et al. (2018) Hypercholesterolemia induces T cell expansion in humanized immune mice. J Clin Invest 128:2370-2375
Martin Carli, Jayne F; LeDuc, Charles A; Zhang, Yiying et al. (2018) FTO mediates cell-autonomous effects on adipogenesis and adipocyte lipid content by regulating gene expression via 6mA DNA modifications. J Lipid Res 59:1446-1460
Arnes, Luis; Liu, Zhaoqi; Wang, Jiguang et al. (2018) Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma. Gut :
Tamucci, Kirstin A; Namwanje, Maria; Fan, Lihong et al. (2018) The dark side of browning. Protein Cell 9:152-163
Accili, Domenico (2018) Insulin Action Research and the Future of Diabetes Treatment: The 2017 Banting Medal for Scientific Achievement Lecture. Diabetes 67:1701-1709
Ravussin, Yann; Edwin, Ethan; Gallop, Molly et al. (2018) Evidence for a Non-leptin System that Defends against Weight Gain in Overfeeding. Cell Metab 28:289-299.e5

Showing the most recent 10 out of 225 publications